Cargando…
Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response
OBJECTIVES: To determine the prognostic value of patterns of right ventricular adaptation in patients with pulmonary arterial hypertension (PAH), assessed using cardiac magnetic resonance (CMR) imaging at baseline and follow-up. METHODS: Patients attending the Sheffield Pulmonary Vascular Disease Un...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380507/ https://www.ncbi.nlm.nih.gov/pubmed/35512982 http://dx.doi.org/10.1136/heartjnl-2021-320733 |
_version_ | 1784768900859166720 |
---|---|
author | Goh, Ze Ming Balasubramanian, Nithin Alabed, Samer Dwivedi, Krit Shahin, Yousef Rothman, Alexander M K Garg, Pankaj Lawrie, Allan Capener, David Thompson, A A Roger Alandejani, Faisal Wild, Jim M Johns, Christopher S Lewis, Robert A Gosling, Rebecca Sharkey, Michael Condliffe, Robin Kiely, David G Swift, Andrew J |
author_facet | Goh, Ze Ming Balasubramanian, Nithin Alabed, Samer Dwivedi, Krit Shahin, Yousef Rothman, Alexander M K Garg, Pankaj Lawrie, Allan Capener, David Thompson, A A Roger Alandejani, Faisal Wild, Jim M Johns, Christopher S Lewis, Robert A Gosling, Rebecca Sharkey, Michael Condliffe, Robin Kiely, David G Swift, Andrew J |
author_sort | Goh, Ze Ming |
collection | PubMed |
description | OBJECTIVES: To determine the prognostic value of patterns of right ventricular adaptation in patients with pulmonary arterial hypertension (PAH), assessed using cardiac magnetic resonance (CMR) imaging at baseline and follow-up. METHODS: Patients attending the Sheffield Pulmonary Vascular Disease Unit with suspected pulmonary hypertension were recruited into the ASPIRE (Assessing the Spectrum of Pulmonary hypertension Identified at a REferral Centre) Registry. With exclusion of congenital heart disease, consecutive patients with PAH were followed up until the date of census or death. Right ventricular end-systolic volume index adjusted for age and sex and ventricular mass index were used to categorise patients into four different volume/mass groups: low-volume-low-mass, low-volume-high-mass, high-volume-low-mass and high-volume-high-mass. The prognostic value of the groups was assessed with one-way analysis of variance and Kaplan-Meier plots. Transition of the groups was studied. RESULTS: A total of 505 patients with PAH were identified, 239 (47.3%) of whom have died at follow-up (median 4.85 years, IQR 4.05). The mean age of the patients was 59±16 and 161 (32.7%) were male. Low-volume-low-mass was associated with CMR and right heart catheterisation metrics predictive of improved prognosis. There were 124 patients who underwent follow-up CMR (median 1.11 years, IQR 0.78). At both baseline and follow-up, the high-volume-low-mass group had worse prognosis than the low-volume-low-mass group (p<0.001). With PAH therapy, 73.5% of low-volume-low-mass patients remained in this group, whereas only 17.4% of high-volume-low-mass patients transitioned into low-volume-low-mass. CONCLUSIONS: Right ventricular adaptation assessed using CMR has prognostic value in patients with PAH. Patients with maladaptive remodelling (high-volume-low-mass) are at high risk of treatment failure. |
format | Online Article Text |
id | pubmed-9380507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-93805072022-08-30 Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response Goh, Ze Ming Balasubramanian, Nithin Alabed, Samer Dwivedi, Krit Shahin, Yousef Rothman, Alexander M K Garg, Pankaj Lawrie, Allan Capener, David Thompson, A A Roger Alandejani, Faisal Wild, Jim M Johns, Christopher S Lewis, Robert A Gosling, Rebecca Sharkey, Michael Condliffe, Robin Kiely, David G Swift, Andrew J Heart Pulmonary Vascular Disease OBJECTIVES: To determine the prognostic value of patterns of right ventricular adaptation in patients with pulmonary arterial hypertension (PAH), assessed using cardiac magnetic resonance (CMR) imaging at baseline and follow-up. METHODS: Patients attending the Sheffield Pulmonary Vascular Disease Unit with suspected pulmonary hypertension were recruited into the ASPIRE (Assessing the Spectrum of Pulmonary hypertension Identified at a REferral Centre) Registry. With exclusion of congenital heart disease, consecutive patients with PAH were followed up until the date of census or death. Right ventricular end-systolic volume index adjusted for age and sex and ventricular mass index were used to categorise patients into four different volume/mass groups: low-volume-low-mass, low-volume-high-mass, high-volume-low-mass and high-volume-high-mass. The prognostic value of the groups was assessed with one-way analysis of variance and Kaplan-Meier plots. Transition of the groups was studied. RESULTS: A total of 505 patients with PAH were identified, 239 (47.3%) of whom have died at follow-up (median 4.85 years, IQR 4.05). The mean age of the patients was 59±16 and 161 (32.7%) were male. Low-volume-low-mass was associated with CMR and right heart catheterisation metrics predictive of improved prognosis. There were 124 patients who underwent follow-up CMR (median 1.11 years, IQR 0.78). At both baseline and follow-up, the high-volume-low-mass group had worse prognosis than the low-volume-low-mass group (p<0.001). With PAH therapy, 73.5% of low-volume-low-mass patients remained in this group, whereas only 17.4% of high-volume-low-mass patients transitioned into low-volume-low-mass. CONCLUSIONS: Right ventricular adaptation assessed using CMR has prognostic value in patients with PAH. Patients with maladaptive remodelling (high-volume-low-mass) are at high risk of treatment failure. BMJ Publishing Group 2022-09 2022-05-05 /pmc/articles/PMC9380507/ /pubmed/35512982 http://dx.doi.org/10.1136/heartjnl-2021-320733 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Pulmonary Vascular Disease Goh, Ze Ming Balasubramanian, Nithin Alabed, Samer Dwivedi, Krit Shahin, Yousef Rothman, Alexander M K Garg, Pankaj Lawrie, Allan Capener, David Thompson, A A Roger Alandejani, Faisal Wild, Jim M Johns, Christopher S Lewis, Robert A Gosling, Rebecca Sharkey, Michael Condliffe, Robin Kiely, David G Swift, Andrew J Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
title | Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
title_full | Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
title_fullStr | Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
title_full_unstemmed | Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
title_short | Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
title_sort | right ventricular remodelling in pulmonary arterial hypertension predicts treatment response |
topic | Pulmonary Vascular Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380507/ https://www.ncbi.nlm.nih.gov/pubmed/35512982 http://dx.doi.org/10.1136/heartjnl-2021-320733 |
work_keys_str_mv | AT gohzeming rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT balasubramaniannithin rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT alabedsamer rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT dwivedikrit rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT shahinyousef rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT rothmanalexandermk rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT gargpankaj rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT lawrieallan rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT capenerdavid rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT thompsonaaroger rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT alandejanifaisal rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT wildjimm rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT johnschristophers rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT lewisroberta rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT goslingrebecca rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT sharkeymichael rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT condlifferobin rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT kielydavidg rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse AT swiftandrewj rightventricularremodellinginpulmonaryarterialhypertensionpredictstreatmentresponse |